Healthy adults given vancomycin then VE202 consortium
273 stool samples from healthy adult volunteers in a phase 1 trial, who received antibiotic (vancomycin) pretreatment followed by the live biotherapeutic product VE202, a defined 16-strain bacterial consortium. machine-written summary
273 samples · 273 runs · BE · Adult · 2026 · 1.37 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 2,730 sample values (collection date, country, intervention, intervention detail, latitude, location locality, location region, longitude) |
| ✓ Abstract / description | 819 sample values (antibiotic exposure, health condition, health condition detail) |
| – Full text | no open-access full text linked |
| – Supplementary tables | no supplementary tables available (or none open access) |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention · arms resolved
24 people have samples in more than one arm.
Antibiotic given as the study intervention (incl. eradication therapy Defined bacterial consortium / live biotherapeutic product design randomized_controlled_trial · population healthy_control · Oral vancomycin pretreatment then VE202 16-strain bacterial consortium, single/multiple dose
“received oral vancomycin 125 mg four times daily for 5 days” — abstract:41342324 (study level; per-sample arms are in the intervention column below)
longitudinal
24 of 24 people sampled more than once (273 samples; median 10, up to 14 per person) · follow-up median 7 mo (max 7 mo) · median interval between samples 7 d (time from collection dates). Schedule stated by the source: “24 subjects sampled at up to 14 timepoints (median 10) from Screening/Day -07 through Day 176-182.” (time origin: intervention start); stated follow-up 6 mo.
Each row is one person (24 shown); dots are samples at days since that person's first sample.
No Sandpiper profile for this project's samples yet.
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 273 | 100% | ||||
| country | 273 | 100% | 273 | |||
| health_condition | 273 | 100% | 273 | |||
| subject_id | 273 | 100% | 273 | |||
| antibiotic_exposure | 273 | 100% | 273 | |||
| collection_date | 273 | 100% | 273 | |||
| detailed_location | 273 | 100% | ||||
| health_condition_detail | 273 | 100% | 273 | |||
| intervention | 273 | 100% | 273 | |||
| intervention_detail | 273 | 100% | 273 | |||
| latitude | 273 | 100% | 273 | |||
| location_locality | 273 | 100% | 273 | |||
| location_region | 273 | 100% | 273 | |||
| longitude | 273 | 100% | 273 | |||
| timepoint_label | 273 | 100% | 273 |
- A randomized, double-blind, placebo-controlled, single- and multiple-dose phase 1 study of VE202, a defined bacterial consortium for treatment of inflammatory bowel disease: safety and colonization dynamics of a novel live biotherapeutic product in healthy adults. 2026 PMID 41342324 own_data
Archive description
Stool metagenomes from healthy volunteers administered the live biotherapeutic product VE202 in a phase 1 clinical trial.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of adult by deterministic_prior with confidence 0.90. Assay shotgun_dna.
- host external_curation.infant_catalog · “infant triage reason_code age_adult_only”
- body site study.title · “VE202 phase 1 stool metagenomes”
- body site study.description · “Stool metagenomes from healthy”
- life stage external_curation.infant_catalog · “infant triage reason_code age_adult_only”
- life stage study.description · “metagenomes from healthy volunteers administered the live”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN59351967 | antibiotic_exposure | yes | R4 | 0.50 | paper.abstract | received oral vancomycin 125 mg four times daily |
| SAMN59351967 | collection_date | 2019-05-02 | R1 | 0.90 | biosample.attribute:collection_date | 2019-05-02 |
| SAMN59351967 | country | BE | R1 | 0.90 | sample.attr.geo_loc_name | Belgium: Edegem |
| SAMN59351967 | health_condition | healthy_control | R4 | 0.50 | paper.abstract | Thirty-one healthy adults received oral vancomycin |
| SAMN59351967 | health_condition_detail | Healthy volunteers in phase 1 trial | R4 | 0.50 | paper.abstract | Thirty-one healthy adults received oral vancomycin |
| SAMN59351967 | intervention | no_intervention | R1 | 0.90 | biosample.attribute:Visit.Description | Visit.Description: Screening |
| SAMN59351970 | intervention | live_biotherapeutic | R1 | 0.90 | biosample.attribute:treatment | treatment: ACTIVE |
| SAMN59351967 | intervention_detail | screening baseline before dosing; assigned arm: VE202 live biotherapeutic active arm | R1 | 0.90 | biosample.attribute:Visit.Description | Visit.Description: Screening |
| SAMN59351970 | intervention_detail | VE202 live biotherapeutic active arm | R1 | 0.90 | biosample.attribute:treatment | treatment: ACTIVE |
| SAMN59351967 | latitude | 51.0900 | R1 | 0.90 | biosample.attribute:lat_lon | 51.09 N 4.24 E |
| SAMN59351967 | location_locality | Edegem | R1 | 0.85 | biosample.attribute:geo_loc_name | Belgium: Edegem |
| SAMN59351967 | location_region | Flanders | R1 | 0.60 | biosample.attribute:lat_lon | 51.09 N 4.24 E |
| SAMN59351967 | longitude | 4.2400 | R1 | 0.90 | biosample.attribute:lat_lon | 51.09 N 4.24 E |
| SAMN59351967 | subject_id | 473004 | R1 | 0.85 | sample.attr.subject_id | 473004 |
| SAMN59351967 | timepoint_label | Screening | R1 | 0.85 | sample.attr.visit_description | Screening |
Sequencing
273 runs over 273 samples · mean 1.59 Gbp per run (median 1.37 Gbp, total 434.63 Gbp; 273 runs with a base count) · layout PAIRED 273 · platform ILLUMINA 273 · models Illumina NovaSeq 6000 (273) · 0% of runs with a Sandpiper profile · first public 2026-05-13
Authors (13)
Silber JL first · Norman JM · Kanno T · Crossette EM · Szabady R · Menon R · Marko M · Hao LY · Tomsho L · Bhagat S · Yuan A · Olle B · Lamousé-Smith E last
Downloads
PRJNA1463324.csv.gz (8.7 KB) · parquet (82.0 KB) — all 273 samples, every field with route and confidence · PRJNA1463324_determinations.csv.gz (27.1 KB) — 3,549 evidence rows